This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Blue Light for Treating Psoriasis Vulgaris

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Philips Light and Health
ClinicalTrials.gov Identifier:
NCT02004847
First received: November 19, 2013
Last updated: November 17, 2015
Last verified: November 2015
  Purpose
The purpose of this study is to determine the efficacy and safety of a blue light device for treating Psoriasis vulgaris. The study will compare a blue light treated plaque with an untreated control plaque. Additionally, two intensities of blue light are compared.

Condition Intervention
Psoriasis Vulgaris Device: PSO-CT02

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Monocenter, Randomized, Double Blinded, Intraindividual, Exploratory Study of Effectiveness and Safety of 3 Months Treatment With 2 Peak Intensities of 453nm Blue Light for the Treatment of Mild Plaque Type Psoriasis Vulgaris

Resource links provided by NLM:


Further study details as provided by Philips Light and Health:

Primary Outcome Measures:
  • Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity (HI) Group) as Compared to the Control Area at End of Treatment (Visit 7, Week 12). [ Time Frame: baseline and week 12 ]

    In this study only the "local" PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:

    0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked

    A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).



Secondary Outcome Measures:
  • Change From Baseline of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Treatment During the Attack Period (Week 4, Visit 5) [ Time Frame: baseline and week 4 ]

    In this study only the "local" PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:

    0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked

    A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).


  • Change From Week 12 of the Local Psoriasis Area Severity Index (PASI) of the Target Area (High Intensity) as Compared to the Control Area at End of Follow-up [ Time Frame: Week 12 and week 16 ]

    In this study only the "local" PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:

    0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked

    A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).


  • Change From Baseline (Visit 2) of the Local Psoriasis Area Severity Index (PASI) of the Target Area (Low Intensity (LI) Group) as Compared to the Control Area by Week. [ Time Frame: baseline and week 4, 12, 16 ]

    In this study only the "local" PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:

    0 = no sign, 1 = slight, 2 = moderate, 3 = marked,4 = very marked

    A total severity score was calculated as the sum of the three symptom ratings (range 0-12 whereas 0 (best) - 12 (worst)).


  • Difference in Change From Baseline of Local Psoriasis Area Severity Index (PASI) Between Target and Control Area of the High Intensity (HI) Group as Compared to the Low Intensity (LI) Group [ Time Frame: baseline and week 4, 8, 16 ]

    In this study only the "local" PASI (also called local psoriasis severity index - LPSI) was evaluated. The investigator evaluated and graded the severity of erythema, induration, and scaliness as the key symptoms of psoriasis on the study areas using the following scale:

    0. = no sign

    1. = slight
    2. = moderate
    3. = marked
    4. = very marked A total severity score was calculated as the sum of the three symptom ratings (range 0-12).

  • Change From Baseline of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area [ Time Frame: baseline and week 4, 12 ]
    Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.

  • Change From Week 12 (End of Treatment) of Erythema Evaluated by Mexameter of the Target Area of High Intensity (HI) and Low Intensity (LI) as Compared to the Control Area at End of Follow-up [ Time Frame: week 12 and week 16 ]
    Erythema was measured directly after treatment. Mexameter readings ranged from 0 to 100. Higher values describe higher erythema levels.

  • System Usability Scale [ Time Frame: week 12 ]
    At the end of treatment (visit 7), the usability of the investigational device was evaluated by a questionnaire presented to the patient in German. The usability was evaluated by using the System Usability Scale (SUS) which is an effective tool for assessing the usability of a device. It provides an easy-to-understand score from 0 (negative) to 100 (positive).

  • Change From Baseline in Dermatology Life Quality Index (DLQI) [ Time Frame: baseline and week 12 ]
    It is a simple 10-question validated questionnaire. The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. As the change from baseline is calculated negative values in the Outcome Measure Data indicate an improvement in quality of life.

  • Time to First Use of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI) [ Time Frame: patients will be followed for the complete duration of the clinical study for 16 weeks ]
  • Total Duration of Topical Co-treatment With Vitamin D of High Intensity (HI) and Low Intensity (LI) [ Time Frame: week 16 ]
  • Adverse Device Events (Serious and Non-serious) [ Time Frame: week 0, 1, 2, 4, 8, 12, 16 ]

    Adverse device events: Adverse event related to the use of an investigational medical device wich led to any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons.

    Serious adverse device event: Adverse device effect that has resulted in a) led to death, b) led to serious deterioration in the health of the subject, that either resulted in 1) a life-threatening illness or injury, or 2) a permanent impairment of a body structure or a body function, or 3) in-patient or prolonged hospitalization, or 4) medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function, c) led to foetal distress, foetal death or a congenital abnormality or birth defect.



Other Outcome Measures:
  • Hyperpigmentation of "Normal Skin Areas" Surrounding the Target Area Exposed to Blue Light and Control Area Not Exposed to Blue Light- Evaluation by Mexameter [ Time Frame: week 4, 12, 16 ]
    Arbitrary units measured by mexameter. Mexameter readings ranged from 0 to 100. Higher values correspond to higher pigmentation levels.

  • Adverse Events (Serious and Non-serious) [ Time Frame: week 0, 1, 2, 4, 8, 12, 16 ]
  • Thermal Comfort [ Time Frame: week 12 ]
    Questionaire

  • Patient Acceptance of Hyperpigmentation [ Time Frame: week 16 ]
    Questionaire


Enrollment: 47
Study Start Date: September 2013
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: High Intensity (HI) vs control
PSO-CT02 device: Light wavelength 453nm, high intensity, compared to contralateral untreated control plaque on the same patient.
Device: PSO-CT02
The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
Experimental: Low Intensity (LI) vs control
PSO-CT02 device: Light wavelength 453nm, low intensity, compared to contralateral untreated control plaque on the same patient.
Device: PSO-CT02
The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.

Detailed Description:
Blue light has been shown to release bioactive nitric oxide (NO) from nitrite and nitrosated proteins found in high concentrations in the skin. This bioactive NO has many physiological functions regulating immune responses, proliferation / differentiation as well as local blood Perfusion of the skin. The study will test the PSO-CT02 device, an new investigational medical device emitting blue light with a peak wavelength of 453nm on treating localised mild Psoriasis vulgaris. It can be worn on the Skin above the effected skin area. In this study Treatment (target) and control area as well as intensity of blue light are randomized. The control area will serve as reference. 50 Patients will treat the target area daily (at least 5 times/week) at home for an initial treatment period of 4 weeks. During those 4 weeks, patients will return to the study site for safety and effectiveness assessments twice. After this initiation period patients will treat their plaque for further 8 weeks (3 times/week). This is followed by a 4 week follow up phase without treatment.
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated informed consent prior to any study mandated procedure
  2. Good health according to physical examination as determined by the Investigator
  3. Willing and able to comply with study requirements
  4. Skin type I-IV according to Fitzpatrick
  5. Mild plaque-type psoriasis vulgaris with a Psoriasis area severity index (PASI) ≤10 and Body surface area (BSA)

    ≤10 and Dermatology Life quality index (DLQI) ≤ 10 at screening.

  6. Presence of two comparable psoriatic plaques suitable to be defined as study areas as follows:

    1. located on extremities (plaques located on the palms or sole of the feet are not suitable)
    2. Both areas located either on lower or upper extremity
    3. Can be located on the same extremity
    4. Distance between the two study areas > 10cm (border to border)
    5. If lesion is too large to be fully covered, partial treatment possible
  7. Aged ≥ 18 years up to <75 years
  8. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intra-uterine device [IUD] or transdermal contraceptive patch)
  9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study.

Exclusion Criteria:

General

  1. Inmates of psychiatric wards, prisons, or other state institutions
  2. Investigator or any other team member involved directly or indirectly in the conduct of the clinical study
  3. Participation in another clinical trial within the last 30 days
  4. Pregnant or lactating women Medical History
  5. Photodermatosis and/or Photosensitivity
  6. Porphyria and/or hypersensitivity to porphyrins
  7. Patients with current diagnosis of erythrodermic, exfoliative or pustular psoriasis
  8. Congenital or acquired immunodeficiency
  9. Patients with any of the following conditions present on the study areas: Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic Skin
  10. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02004847

Locations
Germany
Department of Dermatology and Allergology, Medical faculty of the RWTH Aachen
Aachen, Germany, 52074
Sponsors and Collaborators
Philips Light and Health
Investigators
Principal Investigator: Verena von Felbert, PD, Dr. Clinic for Dermatology and Allergology, Medical Faculty of the RWTH Aachen, Germany
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Philips Light and Health
ClinicalTrials.gov Identifier: NCT02004847     History of Changes
Other Study ID Numbers: PsoriasisCT02
Study First Received: November 19, 2013
Results First Received: August 12, 2015
Last Updated: November 17, 2015

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on September 21, 2017